Immuno-Oncology Platform

Selvita’s Immuno-Oncology Platform projects aim to provide novel immunotherapies stimulating natural pathogen defense mechanisms of human immune system to recognize, attack and fight cancer. This approach of viral mimicry holds promise to unmask tumors that remained invisible to immune cells or escaped immune surveillance. Selvita’s Immuno-Oncology Platform projects aim to provide novel immunotherapies stimulating natural pathogen defense mechanisms of human immune system to recognize, attack and fight cancer. This approach of viral mimicry holds promise to unmask tumors that remained invisible to immune cells or escaped immune surveillance. 

Selvita’s Immuno-Oncology Platform projects focus on how to turn unresponsive “cold” tumors into “hot” tumors which can respond to immunotherapy. The intention is to empower immune system with small molecule activators training the immune system to fight cancer and sensitize human tumor cells to immune attack. We intend to combine with other immunotherapies across the oncology landscape to increase the benefits to patients.

  • STING Pathway Agonists

Our leading program is focused on STING pathway agonists. STING protein is one of the major players in innate immune activation being a potent trigger of type I interferon (IFN) and pro-inflammatory cytokines. STING agonists facilitate cancer antigen recognition specific to individual patient and his own tumor giving a hope for highly personalized immunotherapy. Additionally, STING agonists promote tumor infiltration by CD8+ T cells, immune system mobilization and long-term memory. The agents kill malignant cells and simultaneously convert them into a cancer-specific therapeutic vaccine.

Currently STING pathway agonist program is at hit-to-lead stage. Selvita’s strategy involves:

  • discovery of STING pathway agonists of unique chemical structure (non-macrocyclic, non-nucleotide with fine-tunable ADME properties to overcome limitations of current known STING agonist)
  • compounds activity in STING-dependent signalling in multiple models (cancer cell lines, human primary cells for several STING haplotypes) to cover wide patient population
  • good DMPK properties to allow both IT and other routes of administration to cover wide tumor spectrum (local lesions and distant metastases).
  • Other Projects

Selvita investigates effective but unexploited targets from TCR activation pathways and cellular nucleic acid sensors. Several undisclosed projects with first-in-class potential is at discovery phase.